Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Tarceva Small Molecule EGFR-Tyrosine Kinase Inhibitor for Cancer

Drug (Brand/Generic)

Tarceva (erlotinib)

Company/Licensee

OSI Pharmaceuticals, Genetech, Roche

Therapy Class

Anti-neoplastic agent

Product Description

EGFR-tyrosine kinase inhibitor

Current Indication

NSCLC

Market Sector

Oncology

Development Status

Approved in US, Europe and Japan
Expand

Go Top